Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial

Lancet

Volumn 360, Issue 9350, 2002, Pages 2018-2025

  Hartung, Hans Peter ^a,b   Gonsette, Richard ^c   König, Nikolaus ^d   Kwiecinski, Hubert ^e,x   Guseo, Andreas ^f,w   Morrissey, Sean P ^b,q   Krapf, Hilmar ^g   Zwingers, Thomas ^h   Albrecht, H ^d   Basedow Rajwich, B ^d   Hofmeister, R ^d   Pollmann W ^d   Starck, M ^d   Beer, K ⁱ   Hopf, H C ⁱ   Kohler J ⁱ   Lensch, E ⁱ   Besinger, U ^j   Vom Dahl, M ^j   Hendrich, A ^j   Loser M ^j   Braun, M ^k   Greiling, H W ^k   Greve, H ^k   Kohl, D ^k   Merkel, M ^k   Conrad, B ^l   Konstanzer, A ^l   Kornhuber, M ^l   Dierkes, W ^m   Munz, T ^m   Zenker, O ^m   Flachenecker, P M ^b   Weilbach, F X ^b   Haas, J ⁿ   Hauser, U ^o   Kompf D ^p   Moser, A ^p   Scholz, J ^p   Weigle, L J ^p   Branas, C ^q   Sadzot, B ^q   Cras, P ^r   Dams, L ^s   Vande Gaer, L ^s   Demonty, L ^c   Lissoir, F ^c   Guillaume, D ^t   Seeldrayers, P ^u   Peeters, B ^v   Hosszu, Z ^w   Jofeju E ^w   Janiec, K ^f   Lubos, L ^f   Waigt, A ^f   Kaminska, A M ^x   Zakrzewska Pniewska, B ^x   more..

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c National Multiple Sclerosis Center   (Belgium)

^d Marianne Strauss Hospital   (Germany)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f Szent György University   (Hungary)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h Fa Estimate GmbH Augsburg   (Germany)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^j Kreiskrankenhaus Ammerland   (Germany)

^k KLINIKUM NÜRNBERG   (Germany)

^l TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^m Wyeth Pharma GmbH   (Germany)

ⁿ MARTIN LUTHER KRANKENHAUS   (Germany)

^o UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^p UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^q LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^r UNIVERSITY OF LIÈGE   (Belgium)

^s ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^t MS en Revalidatiecentrum   (Belgium)

^u Centre Neurologique Fraiture   (Belgium)

^v ERASME HOSPITAL   (Belgium)

^w Lederle   (Belgium)

^x MEDICAL UNIVERSITY OF SILESIA   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MITOXANTRONE; PLACEBO;

ADULT; ALOPECIA; AMENORRHEA; ANEMIA; ARTICLE; BACKACHE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISABILITY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GRANULOCYTOPENIA; HEADACHE; HEALTH STATUS; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; LEUKOCYTE DISORDER; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MOBILIZATION; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; NAUSEA; NEUROMUSCULAR FUNCTION; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; RHINITIS; SCALE UP; SIDE EFFECT; SINUSITIS; STANDARDIZATION; STOMATITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY DYSFUNCTION; URINARY TRACT INFECTION; VIRUS INFECTION;

EID: 0037153729     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)12023-X     Document Type: Article

References (34)

1. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N Engl J Med. 343:2000;938-952.
2. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
3. Ebers G. Natural history of multiple sclerosis. Compston A., Ebers G., Lassmann H., McDonald W.I., Matthews B., Wekerle H. McAlpine's multiple sclerosis. 3rd edn:1998;191-222 Churchill Livingstone, London.
4. Compston A. Treatment and management of multiple sclerosis. Compston A., Ebers G., Lassmann H., McDonald W.I., Matthews B., Wekerle H. McAlpine's multiple sclerosis. 3rd edn:1998;437-498 Churchill Livingstone, London.
5. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 352:1998;1491-1497.
6. Goodkin D.E. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology. 54:(suppl):2000;2352. (abstr).
7. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology. 56:2001;1496-1504.
8. Cohen J.A., Cutter G.R., Fischer J.S., et al. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology. 59:2002;679-687.
9. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
10. Shenkenberg T.D., von Hoff D. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med. 105:1986;67-81.
11. Hartung H.P., Gonsette R., Morrissey S., Fazekas F. Mitoxantrone. Rudick R.A., Goodkin D.E. Multiple sclerosis therapeutics. 1999;335-348 Martin Dunitz, London.
12. Baker D., O'Neill J.K., Davison A.N., Turk J.L. Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone. Clin Exp Immunol. 90:1992;124-128.
13. Watson C.M., Davison A.N., Baker D., et al. Suppression of demyelination by mitoxantrone. Int J Immunopharmacol. 13:1991;923-930.
14. Lublin F.D., Lavasa M., Viti C., Knobler R.L. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol. 45:1987;122-128.
15. Ridge S.C., Sloboda A.E., McReynolds R.A., et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol. 35:1985;35-42.
16. Gonsette R.E., Demonty L. Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology. 40:(suppl 1):1990;261. (abstr).
17. Kappos L., Gold R., Künstler E., et al. Mitoxantrone (Mx) in the treatment of rapidly progressive MS: a pilot study with serial gadolinium (Gd)-enhanced MRI. Neurology. 40:(suppl 1):1990;261. (abstr).
18. Krapf H., Mauch E., Fetzer U., Laufen H., Kornhuber H.H. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology. 37:1995;113-119.
19. Noseworthy J.H., Hopkins M.B., Vandervoort M.K., et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology. 43:1993;1401-1406.
20. Hauser S.L., Dawson D.M., Lehrich J.R., et al. Intensive immunosuppression in progressive multiple sclerosis; a randomised, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 308:1983;173-180.
21. Ramey D.R., Reynauld J.P., Fries J.F. The health assessment questionnaire 1992 - status and review. Arthritis Care Res. 5:1992;119-129.
22. Miller D.H., Barkhof F., Berry I., Kappos L., Scotti G., Thompson A.J. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry. 54:1991;683-688.
23. Edan G., Miller D., Clanet M., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 62:1997;112-118.
24. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet. 337:1991;441-446.
25. Wei L.J., Lachin J.M. Two-sample asymptotically distribution-free tests for incomplete multivariate observations. J Am Stat Assoc. 79:1984;653-661.
26. Zung W.W.K. A self-rating depression scale. Arch Gen Psychiatry. 12:1965;63-70.
27. Edan G., Brochet B., Clanet M., et al. Safety profile of mitoxantrone in a cohort of 800 multiple sclerosis patients. Multiple Sclerosis. 7:2001;S14. (abstr).
28. Dukart G., Barone J.S. An overview of cardiac episodes following mitoxantrone administration. Cancer Treat Symp. 3:1984;35-41.
29. Mather F.J., Simon R.M., Clark G.M., et al. Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep. 71:1987;609-613.
30. Millefiorini E., Gasperini C., Pozzilli C., et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol. 244:1997;153-159.
31. de Castro S., Cartoni D., Millefiorini E., et al. Noninvasive assessment of mitoxantrone in relapsing remitting multiple sclerosis. J Clin Pharmacol. 35:1995;627-632.
32. Goodkin D.E., Stead R., Flanders K., et al. Registry to evaluate mitoxantrone effects in worsening MS (the RENEW Study): a work in progress. Multiple Sclerosis. 7:2001;S129. (abstr).
33. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 39:1996;285-294.
34. Lemez P., Maresova J. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy. Semin Oncol. 25:(suppl 10):1998;61-65.